Eterna Therapeutics Inc. (ERNA)
NASDAQ: ERNA · Real-Time Price · USD
1.070
+0.030 (2.88%)
At close: Nov 4, 2024, 4:00 PM
1.120
+0.050 (4.66%)
After-hours: Nov 4, 2024, 4:02 PM EST
Eterna Therapeutics Revenue
Eterna Therapeutics had revenue of $47.00K in the quarter ending June 30, 2024. This brings the company's revenue in the last twelve months to $162.00K. In the year 2023, Eterna Therapeutics had annual revenue of $68.00K.
Revenue (ttm)
$162.00K
Revenue Growth
n/a
P/S Ratio
34.74
Revenue / Employee
$20,250
Employees
8
Market Cap
5.79M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Sunshine Biopharma | 30.48M |
Kindly MD | 3.10M |
Mainz Biomed | 917.20K |
Mangoceuticals | 866.79K |
Exicure | 500.00K |
Creative Medical Technology Holdings | 17.00K |
ERNA News
- 5 days ago - Eterna Therapeutics Completes Strategic Financial Restructuring with the Aim to Accelerate its Developmental Activities and Long-Term Success - GlobeNewsWire
- 18 days ago - Eterna Therapeutics and Factor Bioscience Announce Exclusive License and Collaboration Agreement to Accelerate Cell Therapy Development for Oncology, Autoimmune, and Rare Diseases - GlobeNewsWire
- 6 months ago - Eterna Therapeutics to Present at the ASGCT 27th Annual Meeting on Development of Beta 2 Microglobulin-Knockout (B2M-KO) iMSC Line with Enhanced Immunosuppressive Activity and Stealthing Features that May Further Augment the Therapeutic Potential of MSCs - GlobeNewsWire
- 6 months ago - Eterna Therapeutics Announces Appointment of Mahendra Rao, PhD, to its Scientific Advisory Board - GlobeNewsWire
- 9 months ago - Eterna Therapeutics Announces the Appointment of Peter Cicala, JD, to its Board of Directors - GlobeNewsWire
- 10 months ago - Eterna Therapeutics Grants New President and CEO Sanjeev Luther Inducement Award Under Nasdaq Listing Rule 5635 (c)(4) - GlobeNewsWire
- 11 months ago - Eterna Therapeutics Names Sanjeev Luther as President and Chief Executive Officer - GlobeNewsWire
- 11 months ago - Eterna Therapeutics Announces $9.2 Million Convertible Debt and Warrant Financing - GlobeNewsWire